263,590 Shares in Celcuity Inc. (NASDAQ:CELC) Purchased by Candriam S.C.A.

Candriam S.C.A. acquired a new position in shares of Celcuity Inc. (NASDAQ:CELC) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 263,590 shares of the company’s stock, valued at approximately $3,450,000. Candriam S.C.A. owned approximately 0.71% of Celcuity at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of CELC. Prospera Private Wealth LLC bought a new position in shares of Celcuity in the third quarter worth approximately $35,000. Bleakley Financial Group LLC bought a new position in shares of Celcuity in the fourth quarter worth approximately $146,000. Y Intercept Hong Kong Ltd bought a new position in shares of Celcuity in the third quarter worth approximately $205,000. SG Americas Securities LLC lifted its stake in shares of Celcuity by 83.2% in the fourth quarter. SG Americas Securities LLC now owns 14,646 shares of the company’s stock worth $192,000 after buying an additional 6,651 shares in the last quarter. Finally, Quest Partners LLC lifted its stake in shares of Celcuity by 227.6% in the third quarter. Quest Partners LLC now owns 18,962 shares of the company’s stock worth $283,000 after buying an additional 13,174 shares in the last quarter. Institutional investors own 63.33% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Celcuity in a research note on Friday, November 15th. Needham & Company LLC upped their target price on shares of Celcuity from $23.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $30.17.

Celcuity Stock Up 6.6 %

CELC opened at $10.64 on Friday. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The firm has a 50 day moving average price of $11.77 and a 200-day moving average price of $13.57. Celcuity Inc. has a twelve month low of $8.53 and a twelve month high of $22.19. The stock has a market capitalization of $395.06 million, a price-to-earnings ratio of -4.08 and a beta of 0.65.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.